Form 4: Galectin Therapeutics CFO Jack Callicutt Reports Stock Option and Restricted Stock Unit Grants

Jack Callicutt, CFO of Galectin Therapeutics, reports the acquisition of stock options and restricted stock units.

Summary

• Jack Callicutt, the Chief Financial Officer of Galectin Therapeutics Inc., filed a Form 4 on January 27, 2025.
• The report details transactions from January 23, 2025, including the acquisition of stock options and restricted stock units.
• Callicutt acquired 65,000 stock options with an exercise price of $1.23, vesting in installments between June 30, 2025, and December 31, 2026, and expiring on January 23, 2035.
• He also acquired 60,000 restricted stock units that vest 100% on the earlier of December 31, 2025, or the signing of a partnership agreement, and convert into common stock on a one-for-one basis.
• Following these transactions, Callicutt directly owns 65,000 stock options and 60,000 restricted stock units.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing detailing executive compensation. The grants themselves are neither overwhelmingly positive nor negative.

Positives

• The grant of stock options and restricted stock units to the CFO aligns his interests with those of the shareholders.
• The vesting schedule of the options and RSUs incentivizes continued service and performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the options and RSUs.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The grants are part of the company's equity incentive plan.

Stakeholder Impact

• The grants align the CFO's interests with shareholders, potentially encouraging value creation.
• The vesting schedule may impact employee morale and retention.

Key Dates